Mycobacterium ulcerans infection: an eponymous ulcer

@article{Meyers2007MycobacteriumUI,
  title={Mycobacterium ulcerans infection: an eponymous ulcer},
  author={Derek H Meyers},
  journal={Medical Journal of Australia},
  year={2007},
  volume={187}
}
  • D. Meyers
  • Published 1 July 2007
  • Medicine, Political Science
  • Medical Journal of Australia
Over the past two decades, the NHS has seen wave after wave of destabilising change. British doctors have had to confront an internal market system (in 1991); general practice fund-holding (1992); abolition of regional health authorities and the creation of nine health offices (1996); abolition of fund-holding (1996); a target plan for improving care and cutting waiting times (2000); the introduction of hospital league tables (2001); primary care trusts taking on the planning and commissioning… 
2 Citations
Understanding Buruli Ulcer (Mycobacterium ulcerans Disease)
TLDR
The activity of mycolactone on human cells strongly suggests that bacterial production of myColactone in vivo favors the establishment of long-term infections by suppressing host immune defenses.
Mycobacterium ulcerans infection
Mycobacterium ulcerans is the causative agent of a new emerging infectious disease, which has been reported in at least 33 countries worldwide with tropical, subtropical and temperate climates (Table

References

SHOWING 1-10 OF 32 REFERENCES
Mycobacterium ulcerans disease.
TLDR
Better understanding of disease transmission and pathogenesis is needed for improved control and prevention of Buruli ulcer and BCG vaccination yields a limited, relatively short-lived, immune protection.
Consensus recommendations for the diagnosis, treatment and control of Mycobacterium ulcerans infection (Bairnsdale or Buruli ulcer) in Victoria, Australia
TLDR
BU is best treated with surgical excision, which, if possible, should include a small rim of healthy tissue, and there is a role for antibiotics for more extensive disease, and their use may allow more conservative surgery.
First case of Mycobacterium ulcerans disease (Bairnsdale or Buruli ulcer) acquired in New South Wales
TLDR
This is the first case of M. ulcerans infection acquired in NSW and, while one case was probably acquired in Papua New Guinea, the other was most likely to have been acquired in southern NSW.
Mycobacterium bovis BCG Vaccination as Prophylaxis against Mycobacterium ulcerans Osteomyelitis in Buruli Ulcer Disease
TLDR
Results show that effective BCG vaccination at birth provides significant protection against the development of M. ulcerans osteomyelitis in children and adults, and health authorities should give attention to the enhancement of neonatalBCG vaccination coverage in all countries of Africa where BU is endemic.
A NEW MYCOBACTERIAL INFECTION IN MAN
  • Medicine
  • 1949
TLDR
It is difficult to be sure if aureomycin exerted more than some favourable influence on seriously ill people treated for severe Salmonella infections, but its non-toxicity and ease of administration encourage further trials.
Mycobacterium ulcerans infection (Buruli or Bairnsdale ulcer): challenges in developing management strategies
TLDR
Results of studies on the use of antibiotics, alone or in combination with surgery, are encouraging and suggest that antibiotics should be used in patients with a history of antibiotic-resistant infections.
THE BAIRNSDALE ULCER
  • Education
    The Medical journal of Australia
  • 1972
TLDR
The lack of scientific competence in both the legislative and executive spheres of government has created a kind of no-man's land between science and politics, in which the scientific establishment has considerable freedom from public accountability.
Risk Factors for Adverse Drug Events: A 10-Year Analysis
TLDR
Some risk factors are consistent for all ADEs and across multiple therapeutic classes of drugs, while others are class specific.
Prevention and treatment of infant and childhood vitamin D deficiency in Australia and New Zealand: a consensus statement
TLDR
Regular sunlight exposure can prevent vitamin D deficiency, but the safe exposure time for children is unknown, and high‐dose bolus therapy should be considered for children over 12 months of age if compliance or absorption issues are suspected.
Pharmacogenetics, Drug-Metabolizing Enzymes, and Clinical Practice
TLDR
The current evidence base for pharmacogenetics in relation to drug-metabolizing enzymes is summarized and no other drugs have an evidence base that is sufficient to justify prospective testing at present, although some warrant further evaluation.
...
1
2
3
4
...